Table 2.
Unadjusted comparisons of the measured clinical outcomes, health resources utilization, and direct medical costs associated with infliximab maintenance therapy and conventional maintenance therapy during 1-year observation time
|
|
IMT, n = 295
|
CMT, n = 130
|
P value | ||||
|
Outcome measure
|
Mean/%
|
SD
|
Median
|
Mean/%
|
SD
|
Median
|
|
| Clinical outcomes | |||||||
| Surgery rate | 12.7% | 25.4% | 0.002b | ||||
| Disease remission rate | 94.6% | 86.9% | 0.008b | ||||
| Utility for quality of life | 0.890 | 0.080 | 0.900 | 0.757 | 0.093 | 0.748 | < 0.001 |
| Newly developed complications | |||||||
| Any complications | 27.0% | 42.3% | 0.002b | ||||
| Anus fistula | 17.4% | 14.6% | 0.489 | ||||
| Intestinal fistula | 3.5% | 4.6% | 0.582 | ||||
| Intestinal obstruction | 4.2% | 12.3% | 0.003b | ||||
| Perianal abscess | 5.8% | 6.2% | 0.886 | ||||
| Bowel perforation | 1.9% | 3.8% | 0.260 | ||||
| Health resource utilization | |||||||
| Outpatient clinic visits | 1.9 | 3.3 | 1.0 | 3.7 | 5.2 | 2.0 | < 0.001 |
| Hospital admissions | 5.3 | 2.2 | 6.0 | 1.4 | 1.0 | 1.0 | < 0.001 |
| Hospital admissions for infliximab administration | 4.4 | 2.2 | 5.0 | 0.0 | 0.0 | 0.0 | < 0.001 |
| Hospital admissions for active disease management | 0.9 | 1.0 | 1.0 | 1.4 | 1.0 | 1.0 | < 0.001 |
| Hospital stay days | 15.2 | 11.1 | 14.0 | 14.8 | 12.4 | 9.5 | 0.207 |
| Hospital stay days related to infliximab administration | 5.7 | 3.8 | 6.0 | 0.0 | 0.0 | 0.0 | < 0.001 |
| Hospital stay days for active disease management | 9.5 | 11.3 | 9.0 | 14.8 | 12.4 | 9.5 | < 0.001 |
| Direct medical costs for outpatient clinic visits | |||||||
| Outpatient costs for drugs | ¥710 | ¥4,268 | ¥0 | ¥2,342 | ¥4698 | ¥644 | < 0.001 |
| Outpatient costs for others | ¥232 | ¥589 | ¥0 | ¥130 | ¥446 | ¥0 | 0.008b |
| Total outpatient costs | ¥942 | ¥4371 | ¥54 | ¥2473 | ¥4777 | ¥810 | < 0.001 |
| Direct medical costs for hospitalizations | |||||||
| Hospital costs related to infliximab administration | ¥5,305 | ¥7650 | ¥3577 | ¥0 | ¥0 | ¥0 | < 0.001 |
| Drug acquisition costs of infliximab | ¥39018 | ¥9610 | ¥39200 | ¥0 | ¥0 | ¥0 | < 0.001 |
| Hospital costs for active disease management | ¥11041 | ¥17982 | ¥4090 | ¥24274 | ¥29285 | ¥9321 | < 0.001 |
| Total hospital costs | ¥55365 | ¥22337 | ¥52155 | ¥24274 | ¥29285 | ¥9321 | < 0.001 |
| Total direct medical costs | ¥56307 | ¥23866 | ¥52476 | ¥26747 | ¥30541 | ¥12503 | < 0.001 |
b
P < 0.01. CMT: Conventional maintenance therapy; IMT: Infliximab maintenance therapy; SD: Standard deviation.